CA2541360A1 - Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia - Google Patents

Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia Download PDF

Info

Publication number
CA2541360A1
CA2541360A1 CA002541360A CA2541360A CA2541360A1 CA 2541360 A1 CA2541360 A1 CA 2541360A1 CA 002541360 A CA002541360 A CA 002541360A CA 2541360 A CA2541360 A CA 2541360A CA 2541360 A1 CA2541360 A1 CA 2541360A1
Authority
CA
Canada
Prior art keywords
antibody
vie
vib
vic
vid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002541360A
Other languages
English (en)
French (fr)
Inventor
Bradley T. Messmer
Nicholas Chiorazzi
Emilia Albesiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2541360A1 publication Critical patent/CA2541360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
CA002541360A 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia Abandoned CA2541360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
US60/509,473 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
CA2541360A1 true CA2541360A1 (en) 2005-04-21

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002541360A Abandoned CA2541360A1 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Country Status (6)

Country Link
US (2) US8119340B2 (https=)
EP (1) EP1678195A4 (https=)
JP (1) JP2007510622A (https=)
AU (1) AU2004279441B2 (https=)
CA (1) CA2541360A1 (https=)
WO (1) WO2005034733A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1678195A4 (en) 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2576621B1 (en) * 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011261396B2 (en) * 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
CA2936092A1 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP3149167B1 (en) * 2014-05-30 2019-09-04 Academia Sinica Aptamer targeting mage-a3 peptide and uses thereof
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3328994A4 (en) * 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56-Faced Antigen-Binding Proteins and Uses Thereof
RU2018107056A (ru) * 2015-08-24 2019-09-26 МЕДИММЬЮН, ЭлЭлСи Полипептиды mrka, антитела к ним и пути их применения
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
WO2018152452A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
EP3934418A4 (en) * 2019-03-08 2023-01-18 Memorial Sloan Kettering Cancer Center ADAM17 BINDING MOLECULES AND USES THEREOF
CN114599678A (zh) 2019-08-12 2022-06-07 希望之城 Il1rap抗体
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc ANTI-ILT2 antibodies and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP1678195A4 (en) 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA

Also Published As

Publication number Publication date
US8119340B2 (en) 2012-02-21
AU2004279441A1 (en) 2005-04-21
EP1678195A4 (en) 2008-04-23
WO2005034733A2 (en) 2005-04-21
US20090117095A1 (en) 2009-05-07
EP1678195A2 (en) 2006-07-12
US9745364B2 (en) 2017-08-29
US20120141462A1 (en) 2012-06-07
WO2005034733A3 (en) 2005-09-09
AU2004279441B2 (en) 2010-07-01
JP2007510622A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
US9745364B2 (en) Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
Messmer et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
Marasca et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma
Yang et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires
Hardy et al. A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family.
Pennell et al. Restricted Ig variable region gene expression among Ly-1+ B cell lymphomas.
Fish et al. Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response.
Kipps et al. Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin
CA2445989A1 (en) Colon cancer antigen panel
Jia et al. A novel method of multiplexed competitive antibody binning for the characterization of monoclonal antibodies
Vora et al. Contrasting the in situ behavior of a memory B cell clone during primary and secondary immune responses
Ghosh et al. In situ diversification of the antibody repertoire in chronic Lyme arthritis synovium
Feeney et al. Human cord blood kappa repertoire
Belessi et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia:“CLL‐biased” deletions in a subset of cases with stereotyped receptors
US8722350B2 (en) Methods and compositions for categorizing patients
Hadzidimitriou et al. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases
CA2497107A1 (en) Methods and compositions for categorizing patients
Roers et al. Single-cell PCR analysis of T helper cells in human lymph node germinal centers
Diaw et al. Double producers of kappa and lambda define a subset of B cells in mouse plasmacytomas
Dyer et al. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias
Smilevska et al. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma
Bende et al. Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation
Takishita et al. Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes
Li et al. Repertoire diversification in mice with an IgH-locus-targeted transgene for the rearranged VH domain of a physiologically selected anti-ssDNA antibody
US20050181370A1 (en) Cancer-associated nucleic acids and polypeptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131009